Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Receivables (2021 - 2025)

Apellis Pharmaceuticals filings provide 5 years of Receivables readings, the most recent being $366.7 million for Q4 2025.

  • For the quarter ending Q4 2025, Receivables rose 36.1% year-over-year to $366.7 million, compared with a TTM value of $366.7 million through Dec 2025, up 36.1%, and an annual FY2025 reading of $366.7 million, up 36.1% over the prior year.
  • Receivables hit $366.7 million in Q4 2025 for Apellis Pharmaceuticals, up from $352.0 million in the prior quarter.
  • The five-year high for Receivables was $366.7 million in Q4 2025, with the low at $719000.0 in Q2 2021.
  • Median Receivables over the past 5 years was $172.0 million (2023), compared with a mean of $152.0 million.
  • The sharpest move saw Receivables surged 2191.12% in 2023, then dropped 28.75% in 2025.
  • Year by year, Receivables stood at $10.1 million in 2021, then decreased by 9.49% to $9.1 million in 2022, then skyrocketed by 2191.12% to $209.5 million in 2023, then increased by 28.64% to $269.5 million in 2024, then surged by 36.1% to $366.7 million in 2025.
  • According to Business Quant data, Receivables over the past three periods came in at $366.7 million, $352.0 million, and $220.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.